MedicaidPrior AuthMedium impact
Imjudo (tremelimumab-actl) (New)
Humana·OH · Oncology, Hematology·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has established a new prior authorization policy for Imjudo (tremelimumab-actl), an oncology medication used to treat unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer. Prior authorization is required for all Imjudo prescriptions and must be used in combination with Imfinzi (durvalumab).
Action Required
Before December 1, 2025: Billing team must update prior authorization requirements for Imjudo (tremelimumab-actl) prescriptions for Ohio Medicaid patients. Ensure providers obtain prior authorization before prescribing Imjudo for hepatocellular carcinoma or non-small cell lung cancer patients. Update billing system to flag these cases and add documentation requirements to verify combination therapy with Imfinzi. Claims without prior authorization will be denied.